Henry S. Park, MD, MPH
Cards
Titles
Vice Chair for Clinical Research, Therapeutic Radiology; Chief, Thoracic Radiotherapy Program, Therapeutic Radiology; Chief, RefleXion Program, Therapeutic Radiology; Assistant Medical Director, Clinical Trials Office, Yale Cancer Center; Head of Advisory College, Purple College, Office of Student Affairs
Education
Harvard University, Biostatistics, Epidemiology, Decision Science (2012)
Yale University (2012)
Training
Yale New Haven Hospital, Yale School of Medicine (2017)
Yale New Haven Hospital, Yale School of Medicine (2017)
Titles
Vice Chair for Clinical Research, Therapeutic Radiology; Chief, Thoracic Radiotherapy Program, Therapeutic Radiology; Chief, RefleXion Program, Therapeutic Radiology; Assistant Medical Director, Clinical Trials Office, Yale Cancer Center; Head of Advisory College, Purple College, Office of Student Affairs
Education
Harvard University, Biostatistics, Epidemiology, Decision Science (2012)
Yale University (2012)
Training
Yale New Haven Hospital, Yale School of Medicine (2017)
Yale New Haven Hospital, Yale School of Medicine (2017)
Titles
Vice Chair for Clinical Research, Therapeutic Radiology; Chief, Thoracic Radiotherapy Program, Therapeutic Radiology; Chief, RefleXion Program, Therapeutic Radiology; Assistant Medical Director, Clinical Trials Office, Yale Cancer Center; Head of Advisory College, Purple College, Office of Student Affairs
Education
Harvard University, Biostatistics, Epidemiology, Decision Science (2012)
Yale University (2012)
Training
Yale New Haven Hospital, Yale School of Medicine (2017)
Yale New Haven Hospital, Yale School of Medicine (2017)
About
Titles
Associate Professor of Therapeutic Radiology
Vice Chair for Clinical Research, Therapeutic Radiology; Chief, Thoracic Radiotherapy Program, Therapeutic Radiology; Chief, RefleXion Program, Therapeutic Radiology; Assistant Medical Director, Clinical Trials Office, Yale Cancer Center; Head of Advisory College, Purple College, Office of Student AffairsBiography
Dr. Henry S. Park is a board-certified radiation oncologist who serves as associate professor, vice chair for clinical research, and chief of thoracic radiotherapy for the Department of Therapeutic Radiology at the Yale School of Medicine. For the Yale Cancer Center, he is an assistant medical director of the Clinical Trials Office, through which he leads the radiation oncology committee and is associate leader of the lung clinical research team. For the medical school's Office of Student Affairs, he is the head of one of the six advisory colleges. He has previously held roles as the associate residency program director, medical student electives director, and continuing medical education director for radiation oncology.
Dr. Park received his undergraduate degree from Yale College, master's degree from the Harvard School of Public Health, and medical doctorate degree from the Yale School of Medicine. He completed his internal medicine internship at Harvard Medical School's Beth Israel Deaconess Medical Center before returning to Yale New Haven Hospital for his residency and chief residency in radiation oncology.
Dr. Park subspecializes in radiation therapy for lung cancer and head and neck cancer, maintaining a busy clinical practice in New Haven. He leads a wide-ranging research program in clinical trials, real-world evidence, and health services. He has co-authored over 135 peer-reviewed original research articles and 45 reviews, book chapters, invited editorials, and practice guidelines. He serves as an oral and written boards examiner for the American Board of Radiology and as an active committee member for the American Society for Radiation Oncology, American Radium Society, SWOG, ECOG-ACRIN, and NRG. He has been honored with multiple awards for his contributions to patient care, clinical research, and medical education.
Appointments
Therapeutic Radiology
Associate Professor on TermPrimary
Other Departments & Organizations
Education & Training
- Residency
- Yale New Haven Hospital, Yale School of Medicine (2017)
- Chief Residency
- Yale New Haven Hospital, Yale School of Medicine (2017)
- Internship
- Beth Israel Deaconess Medical Center, Harvard Medical School (2013)
- MPH
- Harvard University, Biostatistics, Epidemiology, Decision Science (2012)
- MD
- Yale University (2012)
- BS
- Yale University, Music, Neurobiology (2007)
Research
Overview
Population-based Outcomes; Health Services Utilization; Health Disparities; Clinical Trials
Medical Subject Headings (MeSH)
ORCID
0000-0002-9366-8514
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Barbara Burtness, MD
Benjamin L. Judson, MD, MBA
Cary Gross, MD
Saral Mehra, MD, MBA, FACS
Kenneth B. Roberts, MD
Kimberly L. Johung, MD, PhD
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Head and Neck Neoplasms
Small Cell Lung Carcinoma
Publications
2024
Opioid prescribing trends and pain scores among adult patients with cancer in a large health system.
Baum L, Soulos P, KC M, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Liberatore M, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. Journal Of Clinical Oncology 2024, 42: 11059-11059. DOI: 10.1200/jco.2024.42.16_suppl.11059.Peer-Reviewed Original ResearchConceptsDocumented painHealth systemOpioid prescribingOpioid prescriptionsOpioid prescribing trendsYale New Haven Health SystemPrescribing trendsMetastatic cancerDocumented pain scoresUS health systemOpioid usePain scoresAdult patientsCalculated predicted probabilitiesFlowsheet dataRetrospective cohort studyRelated harmSolid tumor malignanciesCohort studyCancer painPrescribingContext of cancer treatmentStudy criteriaPainSurgery cohortReal world outcomes of patients with small cell lung cancer (SCLC) presenting with brain metastasis at diagnosis in a single institution health system.
Joseph J, Matera R, Park H, Chiang V, Chiang A. Real world outcomes of patients with small cell lung cancer (SCLC) presenting with brain metastasis at diagnosis in a single institution health system. Journal Of Clinical Oncology 2024, 42: e20136-e20136. DOI: 10.1200/jco.2024.42.16_suppl.e20136.Peer-Reviewed Original ResearchConceptsExtensive-stage small cell lung cancerMedian progression free survivalSmall cell lung cancerGamma knife radiosurgeryMedian overall survivalBrain metsCell lung cancerBrain metastasesFree survivalBrain radiationExtensive-stage small cell lung cancer patientsPatients treated with Gamma Knife radiosurgeryLung cancerSmall cell lung cancer patientsAggressive lung cancer subtypePatients treated with chemoimmunotherapyUpfront gamma knife radiosurgerySingle-institution retrospective studyAdvanced radiation techniquesTreated with chemoimmunotherapyProgression free survivalOutcomes of patientsLung cancer subtypesFrontline chemoimmunotherapyPlatinum doubletsRadioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy
Verma N, Laird J, Moore N, Hayman T, Housri N, Peters G, Knowlton C, Jairam V, Campbell A, Park H. Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy. Advances In Radiation Oncology 2024, 9: 101500. PMID: 38699671, PMCID: PMC11063223, DOI: 10.1016/j.adro.2024.101500.Peer-Reviewed Original ResearchAltmetricConceptsLocal recurrence-free survivalNon-lung primaryAssociated with higher local recurrence-free survivalProgression-free survivalBiologically effective doseLocal controlRadioresistant metastasesOverall survivalPulmonary metastasesPrimary cancerColorectal carcinomaAssociated with superior local controlMultivariate analysisPatients treated with radiotherapyRisk of local recurrenceMedian follow-up timeMultivariable Cox proportional hazards regressionInferior local controlMedian total doseSuperior local controlAssociated with decreased riskImpact of histologyMetastasis-free survivalRecurrence-free survivalLocal failureStereotactic Body Radiotherapy in Locally Advanced Non–Small Cell Lung Cancer—Is This the Future?
Lester-Coll N, Park H. Stereotactic Body Radiotherapy in Locally Advanced Non–Small Cell Lung Cancer—Is This the Future? JAMA Oncology 2024, 10: 360-361. PMID: 38206616, DOI: 10.1001/jamaoncol.2023.5856.Peer-Reviewed Original ResearchAltmetric
2023
Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex
Jairam V, Soulos P, Madhav K, Gross C, Slotman B, Chiang A, Park H. Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex. Advances In Radiation Oncology 2023, 9: 101413. PMID: 38778819, PMCID: PMC11110031, DOI: 10.1016/j.adro.2023.101413.Peer-Reviewed Original ResearchAltmetricConceptsExtensive-stage small-cell lung cancerConsolidative thoracic radiotherapyProgression-free survivalSmall cell lung cancerCell lung cancerCREST trialThoracic radiotherapyLung cancerElectronic health record-derived databaseFirst-line systemic therapyStandard first-line treatmentCox proportional hazards regressionFirst-line treatmentNational practice patternsProportional hazards regressionSuperior OSInitial chemotherapyBaseline characteristicsSystemic therapyMale patientsFemale patientsPatient sexHazards regressionSurvival outcomesPractice patternsDose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy
Sasse A, Oh P, Saeed N, Yang D, Hayman T, Knowlton C, Peters G, Campbell A, Laird J, Housri N, Park H. Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy. Practical Radiation Oncology 2023, 14: e97-e104. PMID: 37984711, DOI: 10.1016/j.prro.2023.11.006.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMean lung doseHypofractionated radiation therapyRisk of gradeRadiation pneumonitisLung V20Lung V5Dose-volume predictorsDosimetric risk factorsLogistic regression analysisGrade 5 casesSingle healthcare systemPrimary endpointDose regimensMultivariable analysisLung doseThoracic tumorsDosimetric variablesRisk factorsPneumonitisRadiation therapyCommon treatmentClinical practicePatientsSignificant associationPotential predictorsTrends in new and persistent opioid use in older adults with and without cancer
Baum L, KC M, Soulos P, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Trends in new and persistent opioid use in older adults with and without cancer. Journal Of The National Cancer Institute 2023, 116: 316-323. PMID: 37802882, DOI: 10.1093/jnci/djad206.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAdditional opioid useNew opioid useOpioid useNon-metastatic cancerPersistent opioid useRetrospective cohort studySolid tumor malignanciesClinical strataEligible patientsNaïve patientsOpioid prescribingMetastatic patientsSurgery patientsCohort studySEER-MedicareMetastatic cancerPatientsTumor malignancyCancerOlder adultsSurgeryRandom sampleAdditional useChemotherapyPrescribingPre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer
Peters G, Talcott W, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer. Journal Of Gastrointestinal Oncology 2023, 14: 1181-1192. PMID: 37435226, PMCID: PMC10331751, DOI: 10.21037/jgo-22-1005.Peer-Reviewed Original ResearchCitationsAltmetricConceptsProgression-free survivalMedian progression-free survivalOverall survivalIC-CRTInduction chemotherapySingle-institution retrospective cohort studyPre-operative chemoradiotherapyAdvanced esophageal cancerAdvanced esophageal carcinomaPathologic complete responseRetrospective cohort studyKaplan-Meier methodSubset of patientsProportional hazards regressionCycles of inductionAdenocarcinoma histologyCRT cohortCohort studyComplete responsePathologic responseTreatment cohortsDistant metastasisHazards regressionEsophageal cancerEsophageal carcinoma
2022
Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer
Saeed N, Jin L, Amini A, Verma V, Lester-Coll N, Chen P, Decker R, Park H. Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer. American Journal Of Clinical Oncology 2022, 46: 66-72. PMID: 36662872, DOI: 10.1097/coc.0000000000000974.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsNon-small cell lung cancerStage I non-small cell lung cancerOverall survivalCell lung cancerLung cancerStereotactic body radiation therapyNational Cancer DatabaseLog-rank testBody radiation therapyOptimal fractionation scheduleMultivariable modeling techniquesOS benefitHypofractionated radiotherapySurvival impactMultivariable analysisCox regressionCancer DatabaseRetrospective analysisFractionation schedulesRadiation therapyHFRTPatientsCFRTRadiotherapyKaplan-Meier estimatorOutcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood
Qian D, Ulrich B, Peng G, Zhao H, Conneely K, Miller A, Bruner D, Eldridge R, Wommack E, Higgins K, Shin D, Saba N, Smith A, Burtness B, Park H, Stokes W, Beitler J, Xiao C. Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood. International Journal Of Radiation Oncology • Biology • Physics 2022, 115: 1217-1228. PMID: 36410685, DOI: 10.1016/j.ijrobp.2022.11.009.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRecurrence-free survivalWorse recurrence-free survivalOverall survivalMethylation risk scoreRadiation therapyValidation cohortPeripheral bloodDiscovery cohortOutcome stratificationShorter recurrence-free survivalNeck squamous cell carcinomaGastrostomy tube insertionHigher neutrophil countOral cavity cancerAforementioned risk factorsSquamous cell carcinomaPeripheral blood samplesNonmetastatic HNSCCNeutrophil countPrognostic factorsCox regressionPrognostic valueCell carcinomaTube insertionImmune modulation
Clinical Trials
Current Trials
Prospective Data Registry and Quality of Life Assessment of PatientsUndergoing Radiotherapy With the RefleXion Medical Radiotherapy System (PREMIER Registry)
HIC ID2000034887RolePrincipal InvestigatorPrimary Completion Date04/25/2026Recruiting ParticipantsRAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
HIC ID2000033846RolePrincipal InvestigatorPrimary Completion Date04/30/2027Recruiting ParticipantsMRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
HIC ID2000027403RolePrincipal InvestigatorPrimary Completion Date11/15/2025Recruiting ParticipantsA Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
HIC ID2000030031RolePrincipal InvestigatorPrimary Completion Date05/01/2028Recruiting ParticipantsPhase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
HIC ID2000025868RolePrincipal InvestigatorPrimary Completion Date01/31/2030Recruiting Participants
Academic Achievements and Community Involvement
activity Associate Editor
Journal ServiceFrontiers in OncologyDetails07/01/2021 - Presentactivity Committee Member
Professional OrganizationsAmerican Board of Radiology (ABR)Details07/01/2020 - PresentDescriptionWritten Boards Committee, Thoracic Cancers and Sarcomas Categoryactivity Committee Member
Professional OrganizationsAmerican Radium Society (ARS)Details10/01/2021 - PresentDescriptionAppropriateness Use Criteria Thoracic Committeeactivity Committee Member
Professional OrganizationsAmerican Society for Radiation Oncology (ASTRO)Details07/01/2017 - PresentDescriptionCommittee on Health Equity, Diversity, and Inclusion, Education Committee, Abstract Review Committee (Health Services Research, Head and Neck)activity Committee Member
Professional OrganizationsECOG-ACRIN Cancer Research GroupDetails10/01/2021 - PresentDescriptionHead and Neck Core Committee
Clinical Care
Overview
For Henry S. Park, MD, MPH, building deep and long-lasting relationships with his patients is his favorite part of being a radiation oncologist in the Department of Therapeutic Radiology.
“Even during our first consultation visits, I appreciate how my patients and their families are brave enough to show me the most vulnerable side of themselves,” says Dr. Park. “It's important for me to understand their goals, fears and hopes before I begin to work with them on creating a personalized treatment plan,” he says. “I take this level of trust seriously.”
Dr. Park specializes in treating cancer of the lung and the head and neck. He sees patients at the Smilow Cancer Hospital in New Haven, where he uses advanced radiation techniques like stereotactic body radiation therapy, image-guided radiation therapy, and intensity-modulated radiation therapy to treat patients.
“I try my best to provide high-quality and compassionate care to my patients during this difficult period in their lives,” he says. “And it can be incredibly satisfying.”
As an associate professor of therapeutic radiology and vice chair for clinical research at Yale School of Medicine, he is passionate about being involved in research that may lead to further improvements in cancer care. “My goal for every patient is to use radiation in a customized manner in order to maximize the damage we can do to the cancer and minimize side effects that can affect quality of life,” he says.
Clinical Specialties
Fact Sheets
Metastatic Brain Tumors
Learn More on Yale MedicineSmall Cell Lung Cancer
Learn More on Yale MedicinePrimary Brain Tumors
Learn More on Yale MedicineStereotactic Body Radiotherapy (SBRT)
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- June 07, 2024
Yale Cancer Center Researchers and Trainees Present at ASCO
- March 18, 2024
New YSM Colleges Enhance Community and Mentorship
- January 04, 2024
Smilow Cancer Hospital at Yale New Haven becomes first hospital in the northeast to offer SCINTIX biology-guided radiotherapy by RefleXion
- November 14, 2023
Henry S. Park, MD, MPH, in honor of Lung Cancer Awareness Month
Related Links
Get In Touch
Contacts
Locations
Smilow Cancer Hospital at Yale New Haven
Academic Office
35 Park Street, Rm Lower Level 513
New Haven, CT 06511
Business Office
203.200.2659Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.